Skip to main content

Table 1 Patient characteristics – discovery cohort

From: A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases

Patient

Age group

Follow-up time [months]

Creatinine at time of biopsy [mg/dl]

Creatinine at follow-up [mg/dl]

eGFR (MDRD) at time of biopsy [ml/min/1.73 m 2]

eGFR (MDRD) at follow-up [ml/min/1.73 m 2]

Proteinuria at time of biopsy [g/d]

Proteinuria at follow-up [g/d]

Histological diagnosis

SD/PD

Endpoint

IFTA

GS

IFTA + GS = CREDI

II = INSCO

1

2

62

0.84

0.88

>60

>60

1.9

3.2

FSGS

Stable

-

2

2

4

0

2

2

49

0.76

0.84

>60

>60

4.7

4.7 mg/dl

MCD

Stable

-

0

0

0

0

3

4

63

0.79

0.75

>60

>60

500 mg/dl

0.0

MCD

Stable

-

1

1

2

1

4

2

43

1.34

1.09

58.1

>60

0.4

45.1 mg/dl

IGAN

Stable

-

1

2

3

1

5

1

49

0.77

0.76

>60

>60

7.4

43.0

FSGS

Stable

-

0

2

2

0

6

2

39

0.8

0.75

>60

>60

1.6

0.2

MCD

Stable

-

1

1

2

0

7

1

31

1.0

0.96

>60

>60

1.3

14.8 mg/dl

IGAN

Stable

-

1

1

2

1

8

3

52

0.93

0.97

>60

>60

1.3

263.3 mg/dl

IGAN

Stable

-

1

1

2

0

9

1

51

1.89

0.91

44.8

>60

42.0

42.0

FSGS

Stable

-

3

2

5

0

10

2

49

1.43

1.43

40.2

39.5

1.0

0.8

IGAN

Stable

-

3

3

6

1

11

2

50

1.56

1.8

51.8

42.9

1.2

NA

IGAN

Stable

-

2

2

4

0

12

3

67

1.42

2.28

51.6

29.3

2.7

4.6

FSGS

Stable

-

2

2

4

1

13

2

68

1.71

3.63

46.9

20.9

1.6

3.6

IGAN

Progressive

2xCrea

3

2

5

1

14

1

51

1.02

3.5

>60

21

12.0

17.5

FSGS

Progressive

2xCrea

2

3

5

2

15

1

29

1.20

1.81

54.3

33.3

7.5

3.2

IGAN

Stable

-

2

3

5

0

16

4

42

1.50

7.02

34.5

<20

8.5

8.0

MGN

Progressive

ESRD

2

2

4

1

17

1

49

1.87

10.1

33.4

<20

6.5

NA

RPGN

Progressive

ESRD

2

1

3

2

18

2

48

1.27

4.02

47.9

<20

6.5

1.3

LN4

Progressive

2xCrea

4

4

8

3

19

4

56

3.13

3.37

<20

<20

4.0

1.0

MPGN II

Stable

-

2

3

5

1

20

3

31

5.07

6.03

<20

<20

3.4

2.9

MPA

Progressive

ESRD

3

2

5

2

21

3

n.a.

4.67

NA

<20

NA

10.6

NA

IGAN

NA

NA

1

4

5

1

22

2

n.a.

0.71

NA

>60

NA

10.2

NA

FSGS

NA

NA

1

1

2

0

23

2

n.a.

1.12

NA

>60

NA

0.5

NA

IGAN

NA

NA

3

2

5

1

24

2

n.a.

1.09

NA

>60

NA

6.3

NA

FSGS

NA

NA

1

1

2

1

25

1

n.a.

1.0

NA

>60

NA

1.2

NA

IGAN

NA

NA

0

0

0

0

26

3

n.a.

1.4

NA

52.6

NA

10.0

NA

MCD

NA

NA

1

1

2

0

27

4

n.a.

2.44

NA

<20

NA

18.0

NA

MCD

NA

NA

2

1

3

1

Median

33

49

1.42

1.26

  

2.7

3.4

   

2.0

2.0

4.0

1.0

Mean

39

49

1.66

2.64

  

4.0

5.5

   

1.9

2.0

3.8

0.9

SD

17

11

1.12

2.65

  

2.9

6.0

   

1.0

0.9

1.8

0.9

Median S

33

50

1.38

0.96

  

1.9

3.9

   

1.5

2.0

3.5

0.0

Median P

33

49

1.71

6.03

  

6.5

3.3

   

2.5

2.0

5.0

2.0

Mean S

39

49

1.4

1.29

  

3.2

3.9

   

1.5

1.8

3.3

0.4

Mean P

40

48

2.19

6.15

  

5.8

6.3

   

2.7

2.3

5.0

1.8

SD S

17

11

0.72

0.78

  

2.7

1.0

   

NA

NA

NA

NA

SD P

19

12

1.65

2.59

  

2.9

7.5

   

NA

NA

NA

NA

p-value

n.s.

n.s.

n.s.

0.01

  

n.s.

n.s.

   

n.s.

n.s.

n.s.

0.004

  1. FSGS Focal-segmental glomerulosclerosis, MCD Minimal change disease, IGAN IgA-Nephropathy, MGN Membranous glomerulonephritis, RPGN Rapid progressive glomerulonephritis, LN4 Lupus nephritis WHO IV, MPGN II Membranoproliferative glomerulonephritis type II, MPA Microscopic polyangiitis, NA not applicable/ not assessed, IFTA interstitial fibrosis/tubular atrophy, GS glomerular sclerosis, II interstitial inflammation. Median, Mean and standard deviation (SD) for the patients with follow-up and from stable (S) and progressive (P) patients are shown at the bottom of the table. Age groups have been defined as follows: group 1 = age <30 years, 2 = 30–45, 3 = 46–60, 4 = age >60 years. p-values indicate statistical significance comparing clinical data (age, follow-up, creatinine, proteinuria) from stable and progressive patients.